Drug Profile
Research programme: pneumococcal vaccine - SciSparc
Latest Information Update: 10 Feb 2021
Price :
$50
*
At a glance
- Originator NasVax
- Developer Therapix Biosciences
- Class Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pneumococcal infections
Most Recent Events
- 28 Jan 2021 Therapix Biosciences is now called SciSparc
- 29 Jun 2011 Preclinical trials in Pneumococcal infections in Israel (unspecified route)